All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Efficacy of Terbutaline in Conjunction with Erythromycin in Managing Mycoplasma pneumoniae Bronchitis

Author(s): Yulong Tang*
Department of Pediatrics, The Second Peoples’ Hospital of Nantong, Nantong, Jiangsu Province 226002, China

Correspondence Address:
Yulong Tang, Department of Pediatrics, The Second Peoples’ Hospital of Nantong, Nantong, Jiangsu Province 226002, China, E-mail:

This study seeks to assess the efficacy of terbutaline in conjunction with erythromycin in managing Mycoplasma pneumoniae bronchitis. Between September 2022 and August 2023, we chose 87 children diagnosed with Mycoplasma pneumoniae bronchitis, which were admitted to our hospital and subsequently split into an observation group consisting of 45 cases and a control group with 42 cases through random selection. Routine treatments, such as antitussives and antipyretics, were administered to both groups. Meanwhile, the control group was treated with intravenous erythromycin, and the observation group received terbutaline inhalation treatment as an adjunct. The evaluation of the clinical efficacy of both groups involved a scrutiny of various parameters, including the period of symptom resolution, inflammatory markers, immune function indicators, and lung function markers. Comparatively, the observation group exhibited a much higher efficacy, with a total effective rate of 91.11 %, in contrast to the control group (71.43 %, p<0.05). Subsequent to the treatment, the levels of inflammatory markers (high-sensitivity C-reactive protein, tumor necrosis factor-alpha and procalcitonin) in the observation group saw a substantial decline compared to pre-treatment levels, and were lower than those in the control group (p<0.05). For immune function indicators, the observation group displayed considerably higher cluster of differentiation 4+ cell counts and cluster of differentiation 4+/cluster of differentiation 8+ ratios, as well as notably lower cluster of differentiation 8+ cell counts in comparison to the control group (p<0.05). A reduced duration of symptom resolution and disappearance of lung sounds was found in the observation group as opposed to the control group. Furthermore, following the treatment, the lung function markers (forced expiratory volume 1/forced vital capacity %) demonstrated notable improvement in the observation group as opposed to the control group (p<0.05). Terbutaline in conjunction with erythromycin exhibits good efficacy in managing Mycoplasma pneumoniae bronchitis in children. This comprehensive treatment can considerably ameliorate symptoms, decrease inflammation, modulate immune function, and enhance lung function. As a result, it merits clinical endorsement.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report